The Cooper Companies, Inc. $COO Stock Holdings Lifted by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 84.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,747 shares of the medical device company’s stock after buying an additional 24,084 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Cooper Companies were worth $2,982,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. bought a new position in Cooper Companies in the 3rd quarter worth about $2,669,000. Trail Ridge Investment Advisors LLC increased its position in shares of Cooper Companies by 17.1% during the third quarter. Trail Ridge Investment Advisors LLC now owns 12,293 shares of the medical device company’s stock worth $695,000 after acquiring an additional 1,793 shares during the period. V Square Quantitative Management LLC increased its position in shares of Cooper Companies by 18.8% during the third quarter. V Square Quantitative Management LLC now owns 8,698 shares of the medical device company’s stock worth $492,000 after acquiring an additional 1,377 shares during the period. State of Alaska Department of Revenue raised its stake in shares of Cooper Companies by 71.5% during the third quarter. State of Alaska Department of Revenue now owns 41,044 shares of the medical device company’s stock valued at $2,320,000 after acquiring an additional 17,118 shares in the last quarter. Finally, Mather Group LLC. raised its stake in shares of Cooper Companies by 200.5% during the third quarter. Mather Group LLC. now owns 2,521 shares of the medical device company’s stock valued at $143,000 after acquiring an additional 1,682 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

COO has been the subject of a number of research reports. Zacks Research lowered Cooper Companies from a “hold” rating to a “strong sell” rating in a report on Friday, September 11th. Robert W. Baird set a $61.00 price objective on Cooper Companies and gave the stock a “neutral” rating in a research note on Thursday, September 10th. Citigroup restated a “neutral” rating and set a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Barclays raised Cooper Companies to a “hold” rating in a research report on Wednesday, October 7th. Four analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $68.60.

Cooper Companies Trading Up 4.5%

NASDAQ COO opened at $61.65 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The company has a market capitalization of $11.72 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.40 and a beta of 0.83. The company’s 50-day simple moving average is $62.09 and its two-hundred day simple moving average is $65.80. The Cooper Companies, Inc. has a one year low of $51.01 and a one year high of $89.83.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the business posted $0.49 EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its board has approved a stock buyback program on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 22.7% of its stock through open market purchases. Share repurchase programs are often an indication that the company’s board believes its stock is undervalued.

Insider Activity at Cooper Companies

In related news, Director Walter M. Rosebrough, Jr. bought 7,000 shares of the stock in a transaction on Friday, September 11th. The stock was bought at an average price of $54.11 per share, for a total transaction of $378,770.00. Following the completion of the acquisition, the director directly owned 17,000 shares in the company, valued at approximately $919,870. This represents a 70.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Paul A. Keel bought 4,701 shares of the stock in a transaction on Friday, September 11th. The shares were bought at an average price of $53.18 per share, with a total value of $249,999.18. Following the acquisition, the director owned 4,701 shares of the company’s stock, valued at $249,999.18. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 34,701 shares of company stock valued at $1,880,039 over the last ninety days. 2.08% of the stock is owned by company insiders.

Cooper Companies Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.